News | September 26, 2023
Biosergen, Alkem collaborate to develop anti-infective for severe fungal infections
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD)
Lupin has been exclusively marketing these brands in the Indian market since July 2021
Will continue to own a 7.84 per cent stake in Glenmark Life Sciences with the stake reduction
The centralized marketing authorization granted by the EC is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway
The market capitalization of the company stood at Rs. 7,000 crore +
Luran S MED 797S SPF30 is one of the first ASA materials in the market specifically for medical device housings
Fillauer recently announced the launch of the first-ever bio-attributed prosthetic foot shell
This X-ray device is not only low-dose but also lightweight, making it the perfect tool for quick & accurate diagnoses
CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology
Subscribe To Our Newsletter & Stay Updated
